Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics CEO Samuel Kintz sold 526 shares of common stock at an average price of $27.5371 per share on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 1, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 526 shares of common stock.
• The sale was executed at a weighted average price of $27.5371 per share, with individual trades ranging from $27.52 to $27.54.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following the transaction, Kintz directly owns no shares but indirectly owns 1,048,729 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an insider under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape, providing transparency into the transactions of company insiders. Sales under 10b5-1 plans are common and allow insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates